Showing results (101-110 of 209) with videos related to
Sort By:
Pageof 21
The New Zealand Medical Journal|August 16, 2019
A unified national cardiovascular disease (CVD) risk generator is required to address equity in the management of CVD risk in clinical practice in New ZealandAndrew Kerr, Sue Wells, Allan Moffitt, et al.IEEE Reviews in Biomedical Engineering|July 1, 2022
A Mapping Review of Real-Time Movement Sonification Systems for Movement RehabilitationThomas H Nown, Priti Upadhyay, Andrew Kerr, et al.Internal Medicine Journal|May 25, 2020
Increases in early discharge following acute coronary syndrome hospitalisations and associated clinical outcomes in New Zealand between 2006 and 2015: ANZACS-QI-43 studyTom Kai Ming Wang, Corina Grey, Yannan Jiang, et al.Circulation|March 13, 2002
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?R John Simes, Ian C Marschner, David Hunt, et al.The American Journal of Cardiology|September 16, 2003
Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitationIvor L Gerber, Ralph A H Stewart, John K French, et al.Circulation|April 6, 2005
White blood cell count predicts reduction in coronary heart disease mortality with pravastatinRalph A H Stewart, Harvey D White, Adrienne C Kirby, et al.Nephrology (Carlton, Vic.)|February 28, 2020
Impact of chronic kidney disease on mortality and cardiovascular outcomes after acute coronary syndrome: A nationwide data linkage study (ANZACS-QI 44)Helen L Pilmore, Fei Xiong, Yeunhyang Choi, et al.Journal of Medical Physics|January 26, 2010
Practical and clinical considerations in Cobalt-60 tomotherapyChandra P Joshi, Sandeep Dhanesar, Johnson Darko, et al.The American Journal of Cardiology|March 28, 2006
Frequency of recurrent ST-elevation myocardial infarction after fibrinolytic therapy in a different territory as a manifestation of multiple unstable coronary arterial plaquesJohn J Edmond, John K French, Ralph A H Stewart, et al.American Heart Journal|December 21, 2018
Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trialClaes Held, Harvey D White, Ralph A H Stewart, et al.Pageof 21